Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CHKA | P35790 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL518538 | 0.98 | PTGIR (0.76) | PTGIRSIGMAR1HRH3SMN1; SMN2CHKA | |
| SCHEMBL3171551 | 0.98 | PTGIR (0.81) | PTGIRSIGMAR1HRH3SMN1; SMN2CHKA | |
| SCHEMBL1045927 | 0.94 | PTGIR (0.75) | PTGIRSIGMAR1HRH3SMN1; SMN2CHKA | |
| SCHEMBL1043090 | 0.92 | SIGMAR1 (0.77) | PTGIRSIGMAR1HRH3SMN1; SMN2CHKA | |
| SCHEMBL1045386 | 0.92 | SIGMAR1 (0.77) | PTGIRSIGMAR1HRH3SMN1; SMN2CHKA | |
| Hydrochloric Acid SCHEMBL23850638 | 0.92 | PTGIR (0.73) | PTGIRSIGMAR1HRH3SMN1; SMN2CHKA | |
| SCHEMBL1043952 | 0.90 | SIGMAR1 (0.85) | PTGIRSIGMAR1SMN1; SMN2CHKAALDH1A1 | |
| SCHEMBL20804352 | 0.90 | SIGMAR1 (0.85) | PTGIRSIGMAR1SMN1; SMN2CHKAALDH1A1 | |
| SCHEMBL19285228 | 0.90 | SIGMAR1 (0.85) | PTGIRSIGMAR1SMN1; SMN2CHKAALDH1A1 | |
| SCHEMBL30341373 | 0.89 | PTGIR (0.69) | PTGIRSIGMAR1HRH3SMN1; SMN2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304093-A | Piperidone alkaloid and analogues, synthesis method and application thereof | 暨南大学 | 2023-12-29 | — | — | CN | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| CN-114890936-B | Synthesis method of 5, 6-dihydro-2 (1H) -pyridone | 南京师范大学 | 2023-10-03 | — | — | CN | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-114890936-A | Synthetic method of 5, 6-dihydro-2 (1H) -pyridone | 南京师范大学 | 2022-08-12 | — | — | CN | claimed |
| US-20240051974-A1 | DIRECT REDUCTIVE AMINATIONS WITH MONOTRIFLUOROACETOXY BORANE-AMINES | PURDUE RESEARCH FOUNDATION (US) | 2024-02-15 | — | — | US | disclosed |
| CN-117304093-A | Piperidone alkaloid and analogues, synthesis method and application thereof | 暨南大学 | 2023-12-29 | — | — | CN | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| CN-114890936-B | Synthesis method of 5, 6-dihydro-2 (1H) -pyridone | 南京师范大学 | 2023-10-03 | — | — | CN | disclosed |
| CN-114890936-B | Synthesis method of 5, 6-dihydro-2 (1H) -pyridone | 南京师范大学 | 2023-10-03 | — | — | CN | disclosed |
| CN-116694374-A | System for synthesizing 5, 6-dihydro-2 (IH) -pyridone based on photo-thermal and zero pollution extraction | 常州大学 | 2023-09-05 | — | — | CN | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | PTGIR 3368/4885SIGMAR1 2433/4885HRH3 4374/4885 |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | PTGIR 638/4885SIGMAR1 1040/4885HRH3 147/4885 |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | PTGIR 3445/4885SIGMAR1 3897/4885HRH3 4828/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | PTGIR 528/4885SIGMAR1 1170/4885HRH3 1068/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | PTGIR 3368/4885SIGMAR1 2433/4885HRH3 4374/4885 |
| US-20240051974-A1 | DIRECT REDUCTIVE AMINATIONS WITH MONOTRIFLUOROACETOXY BORANE-AMINES | MAOB, BCAT2, AADAT | PTGIR 2518/4885SIGMAR1 2516/4885HRH3 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.